Biosimilars for Simponi: A Guide for UC Patients

For people with ulcerative colitis, the first Simponi biosimilar arrived in the United States in May 2026. Its approval adds a new subcutaneous golimumab option, while the closely related product names make careful checking important. Immgolis references Simponi and includes ulcerative colitis. Immgolis Intri references Simponi Aria and has a different set of approved uses. Knowing which product your prescription names is the starting point for any coverage or switching conversation.

The first Simponi biosimilar for ulcerative colitis

The FDA approved Immgolis and Immgolis Intri in May 2026 as the first biosimilars to Simponi and Simponi Aria. Accord BioPharma is the FDA applicant for both. Immgolis is a subcutaneous injection and is the product relevant to adult ulcerative colitis. Immgolis Intri is an intravenous infusion whose approved uses are rheumatology indications.

For adult ulcerative colitis, the Immgolis prescribing information specifies 200 mg under the skin at week zero, 100 mg at week two, and 100 mg at week six and every four weeks afterward. A new prescription should preserve the clinician's intended dose and timing. Confirm the full product name, strength, pen or syringe presentation, and training needs before the first delivery.

What interchangeable means for Immgolis

FDA designated both products as interchangeable with their respective reference drugs. Under U.S. law, an interchangeable biosimilar may be substituted for its reference product at the pharmacy without prescriber intervention, subject to state pharmacy law. FDA also emphasizes that interchangeability addresses substitution and gives no product a safety or effectiveness ranking. All approved biosimilars must meet the agency's standard of high similarity with no clinically meaningful difference in safety, purity, or potency. The agency's interchangeability explainer provides that distinction.

Patients can still ask to be told which product is dispensed. Record the brand and nonproprietary name from the carton, including its suffix, and check that it matches the medication list. If a clinician intends a specific product, that direction should be reflected in the prescription and handled according to state law. Questions about substitution can be addressed by the gastroenterology office and dispensing pharmacy before a shipment is released.

Insurance and availability implications

FDA approval creates a pathway for use, while real-world access depends on plan formularies, contracting, pharmacy inventory, and launch timing. Self-injected golimumab is commonly handled through a specialty pharmacy, while patients should verify which benefit and dispensing channel their plan uses. Ask whether Immgolis is preferred, whether Simponi remains covered, and whether a new prior authorization is required. Also confirm the allowed specialty pharmacy, effective date, quantity limit, and exact out-of-pocket amount.

The FDA patient guide explains that insurance reimbursement sits outside FDA's role and directs patients to their insurer for coverage details. The Crohn's & Colitis Foundation recommends asking about cost, assistance programs, the timing of a required change, and appeal rights. Because this product was approved recently, checking current stocking and plan status is more reliable than assuming that approval means immediate access.

Preparing for a switch from Simponi

Before changing products, save the authorization, last Simponi dose date, delivery schedule, and a baseline of bowel frequency, bleeding, urgency, pain, and recent biomarkers. After the first Immgolis doses, log injection dates, device problems, injection-site reactions, and changes in ulcerative colitis symptoms. These records give the care team a clearer timeline if the shipment is delayed or symptoms change.

When the first shipment arrives, compare the carton with the prescription and confirm the brand, suffix, strength, quantity, expiration date, and storage instructions. Ask a pharmacist or manufacturer support program for device training if the injection steps differ from the previous pen or syringe. Schedule the refill early enough to resolve a rejected claim before the next four-week dose. Save the pharmacy's shipment confirmation and the insurer's call reference number with the dosing log.

If the insurer announces a future formulary change before the pharmacy can fill Immgolis, ask for a temporary continuity authorization. Give the plan the next dose date and current pharmacy's inventory response, then send the case number to the gastroenterology office. Written timing details help the plan address an access gap before it becomes a missed dose.

Golimumab products carry important safety warnings. The Immgolis label has a boxed warning for serious infections and malignancy and directs clinicians to test for tuberculosis before treatment. Contact the treating team promptly about signs of infection, a suspected severe reaction, a missed dose, or worsening ulcerative colitis. The switch should keep the prescribed schedule intact while the insurer, specialty pharmacy, and gastroenterology office align on the exact product.